Study Design. A prospective cohort study. Objective. The aim of this study was to evaluate the interest of denosumab in the treatment of spinal giant-cells tumors (GCTs) and aneurysmal bone cysts (ABCs). Summary of Background Data. To treat GCTs and ABCs, surgical resection remains the best treatment to limit local recurrence (LR) but constitutes an aggressive treatment with potential morbidity. Denosumab, a human antibody anti-RankL, inhibiting the differentiation of osteoclasts, could be an alternative treatment to avoid aggressive surgery. Methods. Patients suffering from GCTs and ABCs of the spine were included. Patients received a monthly subcutaneous injection of denosumab (120 mg) during a minimum of 6 months either as a neoadjuvant or as an adjuvant therapy. In association with denosumab, an osteosynthesis was added in case of vertebral fracture and a laminectomy in case of spinal cord compression. Clinical and computed tomography (CT)-scan outcomes were analyzed. Results. Eight GCTs and one ABC were included. The mean age was 35 years (range: 22-55 yr). Five patients had neurologic deficit. All patients were operated: six osteosynthesis, one ''en bloc'' resection, four curettages, and two of them associated with an osteosynthesis. Average duration of denosumab therapy was 12.9 months (range: 3.2-24 months). Among them, four patients began denosumab 6 months at least before the surgery. With a mean follow-up of 19.3 months (range: 3.2-52.4 months), back pain and neurologic deficit improved for all patients. Systematic CT-scan at 6 months showed decrease of tumor size and bone consolidation. Regarding patients treated by neoadjuvant denosumab treatment, intraoperative histologic analysis showed an absence of giant cells and a maximum of 10% of alive tumor cells. Conclusion. Denosumab allows bone formation and tumor regression with a maximum efficacy after 6 months of treatment without widely substituting surgery. Long-term results are mandatory to confirm the interest of denosumab and to evaluate LR when stopping denosumab.
T he treatment of primary bone tumors such as giantcells tumors (GCTs) and aneurysmal bone cysts (ABCs) remains a challenging situation because these benign osteolytic tumors can be neurologically and mechanically threatening.
1,2 Furthermore, these tumors can be unresectable or require a mutilating surgical procedure with a risk of neurologic impairment.
GCT is the most common benign bone tumor with low metastatic potential and affects a young population. 3 GCT is composed of three different main cellular components: multinucleated osteoclast-like giant cells, mononuclear spindle-like stromal cells, and mononuclear cells of the monocyte/macrophage lineage. 4 ABCs are osteolytic benign bone tumors, which are characterized by a variable number of giant cells. The giant cells that occur in GCTs and also in ABCs are positive for markers of true osteoclasts. 5 Several authors have demonstrated the main role of the osteoclast differentiation factor overexpressed by giant cells, receptor activator of nuclear factor kappa B (NF-kappaB) ligand (RANK), in the genesis of GCTs, and other benign lesions histologically related to GCTs such as ABCs. 3 Denosumab is a targeted therapy composed of human monoclonal antibody to RANK ligand (RANKL) initially developed to treat severe osteoporosis or multimetastatic osteolytic cancers. 6, 7 Denosumab binds to RANKL and inhibits RANKL to bind to RANK receptor. Consequently inhibiting osteoclast activity, denosumab increases bone mineral density and reduces bone turnover markers. Studies of denosumab versus placebo in the treatment of osteoporosis have demonstrated reductions in vertebral, hip, and nonvertebral fractures. 6 GCTs and ABCs tend to respond poorly to chemotherapy such as biphosphonates and have a high rate of local recurrence. 8 Thus, interest of radiotherapy is controversial. Several authors recommend avoiding radiotherapy to eliminate the risk of radiation-induced sarcomas. 9, 10 In contrast, Ma et al 11 advocated that radiotherapy could be an alternative treatment of unresectable tumors without an evident risk of malignant transformation. ''En bloc'' resection or surgical curettage with cavity filling constitutes the only efficient treatment of those both primary benign bone tumors but these procedures in several cases are impossible because of the invasion of the spinal canal or the vertebral anterior extension. 12 In order to reduce the morbidity of this surgery, several authors suggested the use of denosumab to treat GCT and benign bone tumors histologically related to GCT especially for unresectable tumors. 1, [12] [13] [14] The aim of the present study was to prospectively assess the interest and the efficacy of denosumab in the treatment of GCTs and ABCs located on the spine.
MATERIALS AND METHODS

Population Setting
Patients suffering from either ABCs or GCTs of the spine were included. All patients were prospectively followed in the same institution. The patients were not enrolled if they had any allergy to denosumab or pregnancy. The presence of malignant cells attesting a sarcoma excluded the patient. Before introducing denosumab, a histological diagnosis by open surgical biopsy or computed tomography (CT)-guided biopsy was always achieved as well as a CT-scan of the lesion and a full spine-injected magnetic resonance imaging (MRI). Concerning the GCTs, the possible diagnosis of pulmonary metastasis and neurologic deficit were not exclusion criteria.
Neoadjuvant and Adjuvant Treatments Regimens
All patients have received a monthly subcutaneous injection of denosumab (Figure 1 ). Denosumab is a human monoclonal IG2 antibody. Its target is the receptor activator NFkappab. Before the introduction of the treatment, a phosphoscalcic check-up was processed to seek for hypocalcemia and was controlled before each injection and following the end of the therapy. Furthermore, patients underwent a systematic dental or maxillofacial check-up to prevent the occurrence of osteonecrosis of the jaw. 15 The first subcutaneous injection needed a one-day hospitalization in order to initiate the therapy and to control the potential occurrence of adverse events. Thus, subsequent injections were processed at home. The posology of each dose injected is 120 mg. All patients received a daily intake of calcium and vitamin D excepted in a context of hypercalcemia. Two regimens were possible depending of the clinical presentation of the patient: either injection began 6 months before the surgery as neoadjuvant therapy or immediately after an emergency surgery in case of fracture needing osteosynthesis or spinal cord compression needing laminectomy. The preferred regimen was denosumab as a neoadjuvant therapy. Denosumab was used according to the European Medicines Agency guidelines and United States Food and Drugs Administration. 4, 16, 17 The local ethical committee board previously accepted the therapeutic protocol ( Figure 1 ).
Surgical Procedure
After discussion at the multidisciplinary tumor board, an adjuvant surgical procedure was associated with denosumab. In case of mechanical threat or pathological fracture, we performed a spinal fixation with an open or percutaneous osteosynthesis. In case of spinal cord compression, a laminectomy was added. If the tumor was resectable after the injections of denosumab, an ''en bloc'' resection could be discussed.
Clinical and Radiological Follow-up
Patients were followed at 3, 6, and 12 months since the beginning of denosumab therapy. At each check-up, clinical and radiographic examinations were processed. Clinical examination controlled the intensity of back pain and radicular pain, the evolution of neurological examination, the surgical scar, and the occurrence of adverse events related to denosumab. Radiographic control was achieved with a noninjected spinal CT-scan. The occurrence of neurological deficit during the treatment did not exclude the patient from the protocol. The duration of denosumab therapy was 6 months at least. Continued treatment was decided at 6 months according to clinical and CT-scan results (bone reconstruction and reduction of tumor size).
RESULTS
Population Data
Nine patients were enrolled, who included four male patients and five female patients ( Table 1 ). The mean age was 35 years (range: 22-55 yr). Seven patients suffered from a GCT, one patient an ABC, and one other a GCT associated with contingent of ABC. Four GCTs were localized onto the lumbar spine, one local recurrence of GCT on the thoracic spine after curettage and systemic treatment by biphosphonates, one invading the upper sacrum and the iliosacral joint, and one invading the sacrum (S2 and S3 levels). An ABC at the cervico-thoracic junction and a GCT on C2 vertebra were included too. Before the surgery, all patients suffered from back pain and seven of them had neurologic signs at presentation: four lumbocruralgias, one lumbosciatalgia with a limp and sphincteral dysfunctions, a cervicobrachial neuralgia with a sudden paraparesis, and a pelvic pain with sphincteral dysfunctions. Among them, four pathological fractures were diagnosed.
Surgical Procedures
All patients were operated. Three patients had a preoperative arterial embolization: two of them because containing a tissular contingent of ABC and the third related to huge sacral GCT. Three osteosynthesis without laminectomy were performed in presence of vertebral fracture or instability before introducing denosumab: two posterior percutaneous fixations (lumbar spine) and one open C1-C3 posterior osteosynthesis that was secondarily associated with percutaneous vertebroplasty of C2 after 6 months of denosumab (Figures 2-4) . Two curettages without polymethyl methacrylate (PMMA) cement filling were performed: one case of iliosacral GCT and ABC treated by curettage and lumboiliac osteosynthesis and one curettage for a GCT invading S2 and S3. A GCT located in the L4 lumbar vertebra was treated by curettage without spinal fixation by anterior approach and filled by PMMA cement. One case of local recurrence of thoracic GCT was treated by iterative curettage, filled by allograft bone and open T1-T6 osteosynthesis. A female patient with a large ABC invading the cervicothoracic huge underwent a laminectomy associated with a C4-T4 fixation and curettage in emergency because of sudden paraplegia due to spinal cord compression by the tumor (Figures 5 and 6 ). Furthermore, this patient was pregnant at presentation and underwent a cesarean section in emergency before an arterial embolization and the spinal surgery. Denosumab is a contraindicated drug in pregnancy. An ''en bloc'' hemi-vertebrectomy has been realized for a localized GCT on L3 vertebra by a combined anterior and posterior approach. denosumab injections was noted. Regarding patients treated by neoadjuvant denosumab, intraoperative histologic analysis has showed an absence of giant cells and a maximum of 10% alive tumor cells. Systematic CT-scan at 3 and 6 months showed decrease of tumor size and some bone consolidation. Bone reconstruction was predominant at the periphery of the tumor, but some trabecular bone reconstruction was observed as well. Maximal bone reconstruction was observed 6 months after starting denosumab.
Clinical and Radiographic Outcomes
DISCUSSION
This present study highlighted the benefits of denosumab in the management of GCTs and apparent tumors located in the spine. Surgery is the recognized treatment for GCTs: either ''en bloc'' resection is considered the best treatment of spinal GCTs or intralesional excision with a high risk to local recurrence. 18, 19 Nevertheless, ''en bloc'' resection such as vertebrectomy and hemivertebrectomy are challenging surgeries due to proximity of neural structures and the potential presence of perioperative morbidities. 20, 21 Denosumab can reduce the size of the tumor and induce bone reconstruction. Related to decrease of tumoral volume and enhancement of bone reconstruction, denosumab can improve preoperative neurologic manifestations such as radicular pain in case of compression by tumoral mass. Even if denosumab does not avoid surgery, it simplifies the surgical procedure by reducing tumor size either by a minimally invasive osteosynthesis or by limited resection. Goldschlager et al 1 have reported similar results. They treated five patients suffering from GCTs of the spine and received the same therapeutic protocol as in our study. They obtained a clinically beneficial radiological response and an impressive histological response. Only one patient had no histological response to denosumab with more than 90% of tumor cells found to be viable on histological investigations. Moreover, Lange et al 5 have obtained interesting results using denosumab onto spinal ABCs. After 2 and 4 months of denosumab treatment, the two patients recovered from pain and neurologic symptoms and a tumor regression was observed on MRI check-ups. Denosumab is used on other locations of GCT such as larynx and limbs, and gives equivalent results. Figure 5 . Sagittal T2 short-tau inversion recovery (STIR)-weighted MRI slide of an ABC invading the cervicothoracic hinge and the spinal canal causing a sudden complete paraplegia to a 26-year-old pregnant patient (A). Sagittal CT-scan slide shows the complete disappearance of C7 and T1 vertebrae (white arrow) (B). A C4-T4 posterior emergency osteosynthesis with laminectomy and curettage was performed after the artery embolization and cesarean section. Denosumab has been recently indicated against GCTs and ongoing questions remain. To date, we do not exactly know how long we should treat with denosumab and what long-term complications can appear. Studies have insufficient long-term follow-up. So far, Mattei et al 12 reported the most important follow-up of the literature concerning a case report of GCT located on the axis treated by denosumab (16 months) . Even if we reported in our study a case with a follow-up at 52.4 months, the mean follow-up is still insufficient to conclude on the long-term outcome. Thus, it remains the potential problem of local recurrence after cessation of denosumab treatment. Matcuk et al 25 have exposed a case of rapid recurrence of a GCT of the distal radius in a 24-year-old woman after cessation of 2-year denosumab therapy. Despite reinitiating denosumab therapy, tumor continued growing and the patient had to be amputed. This case report emphasizes the necessity to surgically remove the tumor in addition to denosumab. This neoadjuvant therapy certainly reduces the tumor volume but does not eradicate it. Moreover, the efficacy of denosumab seems to decrease over time. In the present study, we noticed that denosumab seems to reach maximum efficacy during the first 6 months of denosumab therapy and then reach a plateau. Mak et al 26 have studied the histological outcome of GCTs during denosumab treatment. RANKL expression and giant cells completely disappeared, but neoplastic stroma cells continued proliferating despite denosumab injections. In our study, histologic findings after a neoadjuvant treatment have shown disappearance of giant cells but 10% tumoral cells remained with a risk of local recurrence after stopping denosumab. These conclusions advocate for a systematic surgery of resection in the therapeutic protocol to remove these persistent tumoral cells resistant to denosumab. Denosumab in neoadjuvant therapy decreases the size of the tumor, subsequently allowing less aggressive and mutilating surgical resection especially for initially unresectable GCT but incompletely eradicate it.
22-24
We have no adverse events in this series, but some authors have reported some related to denosumab therapy. 7, 27, 28 Gossai et al 29 reported critical hypercalcemia needing specific medical treatment following discontinuation of denosumab therapy for metastatic giant cell tumor of bone. This hypercalcemia was attributed to rebound osteoclast activity. Aponte-Tinao et al 30 have evoked that denosumab may be responsible to malignant transformation of a GCT without radiotherapy exposure even if it is the only one reported case in the literature and the responsibility of denosumab is uncertain. Thus, denosumab combined with risk factors such as dental extraction, poor oral hygiene, use of removable apparatus, and chemotherapy may favor the development of osteonecrosis of the jaw explaining the systematic pretherapeutic dental check-up in the present study. 15, 31 Boquete-Castro et al 31 in a systematic review of the literature have found an overall incidence of osteonecrosis of the jaw in patients with cancer receiving denosumab at 1.7%. However, majority of these complications remains rare and the therapeutic use of denosumab can be considered as safe.
Denosumab is an effective neoadjuvant therapy against GCT. Even if this therapy does not avoid surgery in most of cases due to the local recurrence risk at the end of the treatment, it considerably decreases the morbidity of the surgery by reducing the tumor volume. Long-term results should confirm these preliminary results to determinate the duration of the treatment, the number of injections and the efficiency of the treatment, and the occurrence of adverse events. Prescription of denosumab has to be managed by a specialized center because long-term effect of denosumab in this field remains unknown till date.
Key Points
Giant-cells tumors (GCTs) and aneurismal bone cysts (ABCs) are benign primitive bone tumors for which surgical resection is the only treatment to eradicate them. Denosumab is a human antibody anti-RankL, inhibiting the differentiation and proliferation of osteoclasts, which have a key role in the development of GCTs and ABCs. In the objective to reduce the morbidity of surgical resection, denosumab is prescribed as a neoadjuvant or adjuvant treatment of GCTs and ABCs developed on the spine. At a mean follow-up of 19.3 months (range: 3.2-52.4 months), denosumab reduces tumor size, induces bone formation in the periphery of the tumor but does not avoid less invasive surgical procedure.
